In one of the most extensive real-world KRAS G12C analyses (N = 743) ever conducted across multiple lines of therapy (67% of patients received ICI therapy), the OS for the NSCLC G12C sub-cohort was similar to that for all the NSCLC patients (15.2 vs. 14.8 months) [37]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.